MPM Bioimpact LLC Purchases 240,435 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

MPM Bioimpact LLC grew its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 109.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 459,943 shares of the biotechnology company's stock after buying an additional 240,435 shares during the period. MPM Bioimpact LLC owned approximately 1.70% of Arcturus Therapeutics worth $7,805,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Wellington Management Group LLP increased its position in shares of Arcturus Therapeutics by 0.8% in the fourth quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company's stock worth $1,647,000 after purchasing an additional 742 shares during the period. Ameriprise Financial Inc. increased its position in shares of Arcturus Therapeutics by 5.0% in the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock worth $316,000 after purchasing an additional 883 shares during the period. Virtus ETF Advisers LLC increased its position in shares of Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 1,132 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Arcturus Therapeutics by 7.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company's stock worth $323,000 after purchasing an additional 1,279 shares during the period. Finally, Brevan Howard Capital Management LP increased its position in shares of Arcturus Therapeutics by 13.7% in the fourth quarter. Brevan Howard Capital Management LP now owns 12,305 shares of the biotechnology company's stock worth $209,000 after purchasing an additional 1,486 shares during the period. Institutional investors own 94.54% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group decreased their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the company a "buy" rating in a research report on Monday, March 10th. Wells Fargo & Company reduced their price target on Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of "Buy" and an average price target of $57.80.

Arcturus Therapeutics Stock Up 3.8%

ARCT traded up $0.45 during trading on Monday, hitting $12.10. The company's stock had a trading volume of 215,350 shares, compared to its average volume of 450,880. The stock's fifty day moving average price is $11.54 and its 200-day moving average price is $15.17. The firm has a market capitalization of $328.03 million, a P/E ratio of -5.45 and a beta of 2.36. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.